WINDTREE THERAPEUTICS INC /DE/ Research and Development Expense
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Research and Development Expense of $1.90 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2025-11-19
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for the quarter ending 2025-09-30 was $1.90M, a 3.61% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for the quarter ending 2025-06-30 was $2.18M, a 77.88% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for the quarter ending 2025-03-31 was $2.27M, a 0.75% increase year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for the quarter ending 2024-12-31 was $2.19M, a 28.20% decline year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for fiscal 2024 was $16.28M, a 95.13% increase from fiscal 2023.
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for fiscal 2023 was $8.34M, a 24.85% decline from fiscal 2022.
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for fiscal 2022 was $11.10M, a 37.60% decline from fiscal 2021.
- WINDTREE THERAPEUTICS INC /DE/ research and development expense for fiscal 2021 was $17.79M, a 15.70% increase from fiscal 2020.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.90M 10-Q · filed 2025-11-19 | $4.08M derived: sum of 2 quarters · filed 2025-11-19 | $6.35M 10-Q · filed 2025-11-19 | $8.54M derived: sum of 4 quarters · filed 2025-11-19 |
| 2025-06-30 | $2.18M 10-Q · filed 2025-08-19 | $4.45M 10-Q · filed 2025-08-19 | $6.64M derived: sum of 3 quarters · filed 2025-08-19 | $8.61M derived: sum of 4 quarters · filed 2025-11-19 |
| 2025-03-31 | $2.27M 10-Q · filed 2025-05-15 | $4.46M derived: sum of 2 quarters · filed 2025-05-15 | $6.43M derived: sum of 3 quarters · filed 2025-11-19 | $16.29M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $4.16M derived: sum of 2 quarters · filed 2025-11-19 | $14.02M derived: sum of 3 quarters · filed 2025-11-19 | $16.28M 10-K · filed 2025-04-15 |
| 2024-09-30 | $1.97M 10-Q · filed 2025-11-19 | $11.83M derived: sum of 2 quarters · filed 2025-11-19 | $14.08M 10-Q · filed 2025-11-19 | $17.14M derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $9.86M 10-Q · filed 2025-08-19 | $12.12M 10-Q · filed 2025-08-19 | $15.17M derived: sum of 3 quarters · filed 2025-08-19 | $17.28M derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | $2.25M 10-Q · filed 2025-05-15 | $5.31M derived: sum of 2 quarters · filed 2025-05-15 | $7.42M derived: sum of 3 quarters · filed 2025-05-15 | $9.18M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | $5.16M derived: sum of 2 quarters · filed 2025-04-15 | $6.93M derived: sum of 3 quarters · filed 2025-04-15 | $8.34M 10-K · filed 2025-04-15 |
| 2023-09-30 | $2.11M 10-Q · filed 2024-11-26 | $3.87M derived: sum of 2 quarters · filed 2024-11-26 | $5.29M 10-Q · filed 2024-11-26 | $6.50M derived: sum of 4 quarters · filed 2024-11-26 |
| 2023-06-30 | $1.76M 10-Q · filed 2024-08-19 | $3.18M 10-Q · filed 2024-08-19 | $4.39M derived: sum of 3 quarters · filed 2024-08-19 | $5.94M derived: sum of 4 quarters · filed 2024-08-19 |
| 2023-03-31 | $1.42M 10-Q · filed 2024-05-15 | $2.63M derived: sum of 2 quarters · filed 2024-05-15 | $4.17M derived: sum of 3 quarters · filed 2024-05-15 | $7.17M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $2.76M derived: sum of 2 quarters · filed 2024-04-16 | $5.75M derived: sum of 3 quarters · filed 2024-04-16 | $11.10M 10-K · filed 2024-04-16 |
| 2022-09-30 | $1.54M 10-Q · filed 2023-11-09 | $4.54M derived: sum of 2 quarters · filed 2023-11-09 | $9.88M 10-Q · filed 2023-11-09 | $14.36M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $3.00M 10-Q · filed 2023-08-07 | $8.34M 10-Q · filed 2023-08-07 | $12.82M derived: sum of 3 quarters · filed 2023-08-07 | $17.50M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $5.34M 10-Q · filed 2023-05-15 | $9.82M derived: sum of 2 quarters · filed 2023-05-15 | $14.50M derived: sum of 3 quarters · filed 2023-05-15 | $18.72M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $4.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $9.16M derived: sum of 2 quarters · filed 2023-03-31 | $13.38M derived: sum of 3 quarters · filed 2023-03-31 | $17.79M 10-K · filed 2023-03-31 |
| 2021-09-30 | $4.68M 10-Q · filed 2022-11-14 | $8.90M derived: sum of 2 quarters · filed 2022-11-14 | $13.31M 10-Q · filed 2022-11-14 | $16.85M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $4.22M 10-Q · filed 2022-08-11 | $8.63M 10-Q · filed 2022-08-11 | $12.17M derived: sum of 3 quarters · filed 2022-08-11 | $16.05M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $4.41M 10-Q · filed 2022-05-05 | $7.95M derived: sum of 2 quarters · filed 2022-05-05 | $11.83M derived: sum of 3 quarters · filed 2022-05-05 | $16.32M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $7.42M derived: sum of 2 quarters · filed 2022-03-31 | $11.91M derived: sum of 3 quarters · filed 2022-03-31 | $15.37M 10-K · filed 2022-03-31 |
| 2020-09-30 | $3.88M 10-Q · filed 2021-11-10 | $8.38M derived: sum of 2 quarters · filed 2021-11-10 | $11.84M 10-Q · filed 2021-11-10 | $13.98M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $4.50M 10-Q · filed 2021-08-05 | $7.96M 10-Q · filed 2021-08-05 | $10.10M derived: sum of 3 quarters · filed 2021-08-05 | $13.89M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $3.46M 10-Q · filed 2021-05-13 | $5.60M derived: sum of 2 quarters · filed 2021-05-13 | $9.39M derived: sum of 3 quarters · filed 2021-05-13 | $12.81M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $2.14M 10-K · filed 2020-04-03 | $5.93M derived: sum of 2 quarters · filed 2020-11-16 | $9.35M derived: sum of 3 quarters · filed 2020-11-16 | $12.69M 10-K · filed 2021-03-29 |
| 2019-09-30 | $3.79M 10-Q · filed 2020-11-16 | $7.21M derived: sum of 2 quarters · filed 2020-11-16 | $10.55M 10-Q · filed 2020-11-16 | $12.91M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $3.41M 10-Q · filed 2020-08-14 | $6.75M 10-Q · filed 2020-08-14 | $9.12M derived: sum of 3 quarters · filed 2020-08-14 | $11.32M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $3.34M 10-Q · filed 2020-05-13 | $5.71M derived: sum of 2 quarters · filed 2020-05-13 | $7.91M derived: sum of 3 quarters · filed 2020-05-13 | $10.79M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $2.37M 10-K · filed 2020-04-03 | $4.57M derived: sum of 2 quarters · filed 2020-04-03 | $7.44M derived: sum of 3 quarters · filed 2020-04-03 | $10.56M 10-K · filed 2020-04-03 |
| 2018-09-30 | $2.20M 10-K · filed 2020-04-03 | $5.08M derived: sum of 2 quarters · filed 2020-04-03 | $8.19M 10-Q · filed 2019-11-14 | $10.61M derived: sum of 4 quarters · filed 2020-04-03 |
| 2018-06-30 | $2.88M 10-K · filed 2020-04-03 | $6.00M 10-Q · filed 2019-08-14 | $8.41M derived: sum of 3 quarters · filed 2020-04-03 | $11.48M derived: sum of 4 quarters · filed 2020-04-03 |
| 2018-03-31 | $3.12M 10-K · filed 2020-04-03 | $5.54M derived: sum of 2 quarters · filed 2020-04-03 | $8.60M derived: sum of 3 quarters · filed 2020-04-03 | $14.08M derived: sum of 4 quarters · filed 2020-04-03 |
| 2017-12-31 | $2.42M 10-K/A · filed 2019-04-23 | $5.48M derived: sum of 2 quarters · filed 2019-04-23 | $10.96M derived: sum of 3 quarters · filed 2019-04-23 | $17.38M 10-K/A · filed 2019-04-23 |
| 2017-09-30 | $3.06M 10-K/A · filed 2019-04-23 | $8.54M derived: sum of 2 quarters · filed 2019-04-23 | $14.96M 10-Q · filed 2018-11-14 | $20.91M derived: sum of 4 quarters · filed 2019-04-23 |
| 2017-06-30 | $5.48M 10-K/A · filed 2019-04-23 | $11.90M 10-Q · filed 2018-08-14 | $17.84M derived: sum of 3 quarters · filed 2019-04-23 | $24.93M derived: sum of 4 quarters · filed 2019-04-23 |
| 2017-03-31 | $6.41M 10-K/A · filed 2019-04-23 | $12.36M derived: sum of 2 quarters · filed 2019-04-23 | $19.44M derived: sum of 3 quarters · filed 2019-04-23 | $27.76M derived: sum of 4 quarters · filed 2019-04-23 |
| 2016-12-31 | $5.95M 10-K · filed 2018-04-17 | $13.03M derived: sum of 2 quarters · filed 2018-04-17 | $21.34M derived: sum of 3 quarters · filed 2018-04-17 | $31.70M 10-K · filed 2018-04-17 |
| 2016-09-30 | $7.08M 10-K · filed 2018-04-17 | $15.40M derived: sum of 2 quarters · filed 2018-04-17 | $25.76M 10-Q · filed 2017-11-14 | $33.98M derived: sum of 4 quarters · filed 2018-04-17 |
| 2016-06-30 | $8.32M 10-K · filed 2018-04-17 | $18.68M 10-Q · filed 2017-08-21 | $26.90M derived: sum of 3 quarters · filed 2018-04-17 | $33.35M derived: sum of 4 quarters · filed 2018-04-17 |
| 2016-03-31 | $10.36M 10-K · filed 2018-04-17 | $18.59M derived: sum of 2 quarters · filed 2018-04-17 | $25.04M derived: sum of 3 quarters · filed 2018-04-17 | $32.17M derived: sum of 4 quarters · filed 2018-04-17 |
| 2015-12-31 | $8.22M 10-K · filed 2017-03-31 | $14.68M derived: sum of 2 quarters · filed 2017-03-31 | $21.81M derived: sum of 3 quarters · filed 2017-03-31 | $28.89M 10-K · filed 2017-03-31 |
| 2015-09-30 | $6.45M 10-K · filed 2017-03-31 | $13.58M derived: sum of 2 quarters · filed 2017-03-31 | $20.66M 10-Q · filed 2016-11-14 | $28.43M derived: sum of 4 quarters · filed 2017-03-31 |
| 2015-06-30 | $7.13M 10-K · filed 2017-03-31 | $14.21M 10-Q · filed 2016-08-10 | $21.98M derived: sum of 3 quarters · filed 2017-03-31 | $28.45M derived: sum of 4 quarters · filed 2017-03-31 |
| 2015-03-31 | $7.08M 10-K · filed 2017-03-31 | $14.85M derived: sum of 2 quarters · filed 2017-03-31 | $21.32M derived: sum of 3 quarters · filed 2017-03-31 | $28.18M derived: sum of 4 quarters · filed 2017-03-31 |
| 2014-12-31 | $7.77M 10-K · filed 2016-03-29 | $14.24M derived: sum of 2 quarters · filed 2016-03-29 | $21.10M derived: sum of 3 quarters · filed 2016-03-29 | $26.69M 10-K · filed 2016-03-29 |
| 2014-09-30 | $6.47M 10-K · filed 2016-03-29 | $13.33M derived: sum of 2 quarters · filed 2016-03-29 | $18.92M 10-Q · filed 2015-11-05 | $24.67M derived: sum of 4 quarters · filed 2016-03-29 |
| 2014-06-30 | $6.86M 10-K · filed 2016-03-29 | $12.45M 10-Q · filed 2015-08-10 | $18.20M derived: sum of 3 quarters · filed 2016-03-29 | $24.77M derived: sum of 4 quarters · filed 2016-03-29 |
| 2014-03-31 | $5.59M 10-K · filed 2016-03-29 | $11.34M derived: sum of 2 quarters · filed 2016-03-29 | $17.92M derived: sum of 3 quarters · filed 2016-03-29 | $24.78M derived: sum of 4 quarters · filed 2016-03-29 |
| 2013-12-31 | $5.75M 10-K · filed 2015-03-16 | $12.33M derived: sum of 2 quarters · filed 2015-03-16 | $19.19M derived: sum of 3 quarters · filed 2015-03-16 | $27.66M 10-K · filed 2015-03-16 |
| 2013-09-30 | $6.57M 10-K · filed 2015-03-16 | $13.44M derived: sum of 2 quarters · filed 2015-03-16 | $21.91M 10-Q · filed 2014-11-07 | $28.00M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $6.86M 10-K · filed 2015-03-16 | $15.34M 10-Q · filed 2014-08-07 | $21.42M derived: sum of 3 quarters · filed 2015-03-16 | $27.17M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $8.47M 10-K · filed 2015-03-16 | $14.56M derived: sum of 2 quarters · filed 2015-03-16 | $20.30M derived: sum of 3 quarters · filed 2015-03-16 | $25.51M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $6.09M 10-K · filed 2014-03-17 | $11.83M derived: sum of 2 quarters · filed 2014-03-17 | $17.04M derived: sum of 3 quarters · filed 2014-03-17 | $21.57M 10-K · filed 2015-03-16 |
| 2012-09-30 | $5.74M 10-K · filed 2014-03-17 | $10.95M derived: sum of 2 quarters · filed 2014-03-17 | $15.48M 10-Q · filed 2013-11-12 | $19.50M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $5.21M 10-K · filed 2014-03-17 | $9.74M 10-Q · filed 2013-08-08 | $13.75M derived: sum of 3 quarters · filed 2014-03-17 | $17.73M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $4.53M 10-K · filed 2014-03-17 | $8.55M derived: sum of 2 quarters · filed 2014-03-17 | $12.53M derived: sum of 3 quarters · filed 2014-03-17 | $17.14M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $4.01M 10-K · filed 2013-03-15 | $8.00M derived: sum of 2 quarters · filed 2013-03-15 | $12.61M derived: sum of 3 quarters · filed 2013-03-15 | $17.23M 10-K · filed 2014-03-17 |
| 2011-09-30 | $3.98M 10-K · filed 2013-03-15 | $8.60M derived: sum of 2 quarters · filed 2013-03-15 | $13.22M 10-Q · filed 2012-11-14 | $17.13M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-06-30 | $4.62M 10-K · filed 2013-03-15 | $9.23M 10-Q · filed 2012-08-14 | $13.15M derived: sum of 3 quarters · filed 2013-03-15 | $17.88M derived: sum of 4 quarters · filed 2013-03-15 |
| 2011-03-31 | $4.62M 10-K · filed 2013-03-15 | $8.53M derived: sum of 2 quarters · filed 2013-03-15 | $13.26M derived: sum of 3 quarters · filed 2013-03-15 | $17.62M derived: sum of 4 quarters · filed 2013-03-15 |
| 2010-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $8.64M derived: sum of 2 quarters · filed 2013-03-15 | $13.00M derived: sum of 3 quarters · filed 2013-03-15 | $17.14M 10-K · filed 2013-03-15 |
| 2010-09-30 | $4.73M 10-Q · filed 2011-11-14 | $9.09M derived: sum of 2 quarters · filed 2011-11-14 | $13.22M 10-Q · filed 2011-11-14 | |
| 2010-06-30 | $4.36M 10-Q · filed 2011-08-15 | $8.50M 10-Q · filed 2011-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |